Disease Landscape and Forecast Insights

Prophylactic therapy for migraine is prescribed to reduce the frequency, severity, and duration of migraine attacks and to increase the responsiveness of these attacks to acute treatment. Generic…

Migraine is a neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…

Questions answered What patient shares do key acute therapies and brands garner by line of therapy in newly diagnosed migraine patients? What are the quarterly trends in prescribing of acute…

Prophylactic treatment of migraine is mainly considered for chronic migraine patients or those with episodic migraine who have long-lasting attacks or do not experience sufficient relief with acute…

Prophylactic therapy for migraine is prescribed to reduce migraine frequency, severity, and duration of attacks and to increase responsiveness of attacks to acute treatment. Generic oral AEDs (e.g…

Migraine, which afflicts approximately 72 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment…

Triptans have long been the mainstay of acute treatment of migraine; however, in 2020, three novel oral nontriptan brands—Eli Lilly’s Reyvow, AbbVie / Allergan’s Ubrelvy, and Biohaven’s…

According to Clarivate epidemiology, more than 30 million people in the United States experience migraines. Migraine prophylaxis, despite being underused, is a core treatment approach to reduce the…

Migraine, which afflicts approximately 34 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment…

Since 2018, seven novel drugs have entered the U.S. market for the acute or preventive treatment of migraine, and at least four more are on the short-term horizon. Understanding how prescribers…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key migraine patient populations covering 171 countries and more than 99…

Since 2018, four novel calcitonin gene-related peptide (CGRP)-targeting monoclonal antibodies (MAbs)—Novartis / Amgen’s Aimovig, Eli Lilly’s Emgality, Teva’s Ajovy, and Lundbeck’s Vyepti…